- INHIBITORS OF LIN28 AND METHODS OF USE THEREOF
-
The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cancers.
- -
-
Page/Page column 52; 70; 103
(2021/06/26)
-
- SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
-
The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
- -
-
Paragraph 000395
(2019/06/05)
-
- Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)
-
The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)
- -
-
Paragraph 0716;0721; 0722; 0723; 0724
(2019/06/07)
-
- NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF
-
Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or preventing various diseases mediated by ALK5.
- -
-
Paragraph 0171; 0172
(2019/06/12)
-
- 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE
-
The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.
- -
-
Paragraph 1284; 1285
(2015/11/27)
-
- Synthesis of imidazo[1,2-a]pyridines: "Water-mediated" hydroamination and silver-catalyzed aminooxygenation
-
Aqueous syntheses of methylimidazo[1,2-a]pyridines without any deliberate addition of catalyst are reported. Imidazo[1,2-a]pyrazine and imidazo[2,1-a]isoquinoline were also obtained in good yields under similar conditions. With acetonitrile as solvent, Ag
- Chandra Mohan, Darapaneni,Nageswara Rao, Sadu,Adimurthy, Subbarayappa
-
p. 1266 - 1272
(2013/08/24)
-
- Silver-catalyzed cyclization of N-(prop-2-yn-1-yl)pyridin-2-amines
-
We report herein the silver-catalyzed cycloisomerization of readily available N-(prop-2-yn-1-yl)pyridine-2-amines as a new and practical method for the synthesis of differently substituted 3-methylimidazo[1,2-a]pyridines. The isomerization reactions proce
- Chioua, Mourad,Soriano, Elena,Infantes, Lourdes,Jimeno, M. Luisa,Marco-Contelles, Jose,Samadi, Abdelouahid
-
supporting information
p. 35 - 39
(2013/02/22)
-